Senseonics to take over Eversense CGM commercialization from Ascensia

GERMANTOWN, Md. - Senseonics Holdings, Inc. (NYSE American:SENS) announced Wednesday it will assume responsibility for the global commercialization and distribution of its Eversense continuous glucose monitoring products from Ascensia Diabetes Care beginning January 1, 2026.

According to a memorandum of understanding between the companies, Senseonics will take over all U.S. sales, marketing and commercialization operations, while utilizing transition service agreements through Ascensia for markets outside the U.S. until fully established.

Brian Hansen, currently President of CGM at Ascensia, will join Senseonics as Chief Commercial Officer when the transition begins. The companies are working to develop definitive documentation for the planned transaction.

Senseonics also announced an expanded debt facility of up to $100 million with Hercules Capital, Inc. (NYSE:HTGC) to fund the commercial organization. Hercules Capital, with a market capitalization of $3.47 billion and a P/E ratio of 12.6, has maintained consistent dividend payments for 21 consecutive years, currently offering a substantial 9.8% yield. According to InvestingPro data, the company maintains a "GOOD" overall financial health score.

"I’m thrilled to bring Eversense 365 commercialization back in-house and directly control investment in growing the brand to better serve the needs of patients and providers," said Tim Goodnow, President and CEO of Senseonics, in the press release.

The company expects the change to increase topline revenue and expand margins by eliminating revenue sharing with Ascensia. Senseonics projects gross margin expansion to 50% in 2026, with plans to exceed 70% at scale.

For 2025, Senseonics maintains its global net revenue outlook of approximately $34-38 million, with gross margins expected between 32.5% and 37.5%. The company anticipates approximately doubling its global patient base during 2025, with one-third of revenue generated in the first half and two-thirds in the second half of the year. Want deeper insights into companies like Senseonics and Hercules Capital? InvestingPro offers comprehensive research reports for over 1,400 US stocks, transforming complex financial data into actionable intelligence.

Senseonics develops and manufactures long-term, implantable continuous glucose monitoring systems for people with diabetes. Its Eversense 365 product is described as the first year-long continuous glucose monitor.

The information in this article is based on a company press release statement.

In other recent news, Hercules Capital reported its second-quarter 2025 earnings, revealing mixed results. The company achieved an earnings per share (EPS) of $0.50, exceeding analysts’ expectations of $0.47, representing a 6.38% positive surprise. However, Hercules Capital’s revenue of $88.7 million fell significantly short of the anticipated $128.89 million, missing the mark by 31.18%. In another development, JMP Securities raised its price target for Hercules Capital to $24.00 from $22.00, maintaining a Market Outperform rating. JMP cited the company’s strong performance and its leading position in the venture lending market as reasons for the adjustment. Additionally, Eureka Acquisition Corp, a blank check company, issued a $300,000 sponsor note to Hercules Capital Management Corp. The note, which bears no interest, will provide Eureka with general working capital until it completes its initial business combination. These developments reflect the latest activities surrounding Hercules Capital and its associated entities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.